Filing Flows › Neurocrine Biosciences (NBIX) › Capital expenditures
Neurocrine Biosciences (NBIX) capital expenditures by quarter
Neurocrine Biosciences' capital expenditures were $11.6M in Q3 2026 (third quarter 2026), +49% from Q2 2026. Over the last 6 quarters it ranged from $7.8M (Q2 2026) to $13.2M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $11.6M | +49% | -12% |
| Q2 2026 | $7.8M | -14% | -38% |
| Q1 2026 | $9.1M | -31% | -15% |
| Q3 2025 | $13.2M | +6% | — |
| Q2 2025 | $12.5M | +17% | — |
| Q1 2025 | $10.7M | — | — |
Q3 2026 at a glance
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neurocrine Biosciences' capital expenditures?
Neurocrine Biosciences' capital expenditures were $11.6M in Q3 2026 (third quarter 2026), +49% from Q2 2026.
How has Neurocrine Biosciences' capital expenditures changed?
Over the last 6 quarters it ranged from $7.8M (Q2 2026) to $13.2M (Q3 2025).
Q3 2026 results → · How Neurocrine Biosciences makes money →